Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Capital One Financial Corp. (COF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Capital One Financial Corp. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Capital One Financial Corp. trades at $192.02 (market cap $124.98B). The key difference: Capital One Financial Corp. is far larger — about 27.8× ACADIA Pharmaceuticals Inc.'s market cap, and Capital One Financial Corp. pays a 1.58% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | COF | |
|---|---|---|
Market Cap | $4.49B | $124.98B |
Sector | Health | Financials |
52-Week High | $28.06 | $257.94 |
52-Week Low | $20.06 | $176.10 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Capital One (COF) trades at $202.89, down 1.09% with a bullish technical outlook despite recent earnings misses. The stock shows strong analyst support with 62.5% buy ratings and a $252 consensus target, representing 24% upside. Recent financials reveal revenue growth to $53.43B in 2025 but declining net margins to 4.59%, while cash flow improved significantly to $18.42B. The company faces regulatory scrutiny and credit risk concerns but benefits from Discover integration and expanding software offerings.
COF presents a compelling risk-reward profile with substantial upside to analyst targets, though investors must weigh strong institutional support against margin pressure and economic sensitivity. The Discover acquisition provides long-term scale advantages, but near-term performance depends on credit quality stability and successful integration execution amid potential recessionary headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →
